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Abstract  
 
Biodegradable poly(lactic-co-glycolic acid)(PLGA 50:50) nanoparticles (NPs) were prepared 
and characterized in terms of size, composition, zeta potential and colloidal stability. Surface 
modification of PLGA NPs where primary amino groups were introduced to the Pluronic 
surface layer was developed. This method allows modulation of the charge character of the 
nanoparticle surface and provides functional groups for chemical reactions useful for targeting 
while retaining the aggregation stability of the system. The nanoparticles showed significant 
interaction with model membrane system (DPPC and DPPC+DPPG lipid layers) depending 
on the amount and type of Pluronic applied for stabilization of NPs.  
A new antitubercular drug candidate was encapsulated into the PLGA NPs. The cellular 
uptake and the intracellular efficacy against Mycobacterium tuberculosis (Mtb) of the drug 
and the drug loaded nanoparticulate systems were investigated. These formulations were 
successfully taken up by MonoMac6 human monocyte cells and highly enhanced the 
availability and efficacy of the drug against Mtb which was demonstrated in comparative in 
vitro experiments.  
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1 Introduction 
Polymeric nanoparticles (NPs), typically in the size range of 20-300 nm, have attracted 
great attention in the study of drug delivery systems. Biodegradable polymers like poly(lactic-
co-glycolic acid) copolymers, PLGAs are the most common to prepare drug carrying 
nanoparticles. The incorporated drug is physically and uniformly dispersed in the matrix of 
polymer nanoparticles in most cases. Important advantages associated with the use of these 
particulate vehicles are the ability to increase solubility of the drug, protect drugs from 
degradation, controlled and sustained release, and various routes of administration, including 
oral, nasal, intra-ocular or parenteral [1-3]. Furthermore, they offer a means for the localized 
or targeted delivery of drugs to specific tissue/organ sites of interest. The beneficial 
consequences of those properties are the reduced toxicity and considerably limited side 
effects. 
 To exploit the advantageous pharmaceutical behaviour of PLGA drug delivery 
nanoparticles they have to meet the requirements of stability in biological fluids, circulation 
for a prolonged time in the body without the risk of aggregation [4]. It is known that 
unwanted capture of colloidal particles by the mononuclear phagocyte system (MPS) can be 
avoided if the particles are surface modified by the adsorption or grafting of hydrophilic 
polymers such as polyethylene glycol (PEG). The attached PEG layer provides a steric barrier 
to the adsorption of plasma components and as a consequence opsonisation is greatly reduced. 
This steric barrier of PEG coated particles have been shown to present extended circulation 
time and concurrently generates the colloidal stability [5]. Nanoparticles with stealth 
properties that can circumvent clearance and defence mechanisms are the most promising 
formulations [6]. The responsive character of PEG [7] can even be utilized for drug 
incorporation [8].  
Various techniques for formation of PEG layer on PLGA surface were developed. The 
activation and chemical coupling [9,10] yields a stable layer but is accompanied by partial 
degradation of the polyester. The PEG-containing triblock copolymer (Pluronic) proved to be 
an efficient surface modifier which can be applied in a blend form since it is miscible with 
PLGA in a certain concentration range depending on their composition [11-13]. The 
adsorption of Pluronic is however, the most simple and straightforward method to coat PLGA 
nanoparticles [5]. The adsorbed layer is sufficiently stable as it was demonstrated in film 
experiments [14] and several other studies [15,16]. 
Considering the nanoparticle drug formulations in clinical trials the anticancer therapy 
is the most extensively studied and developed area [4,6,8,17]. Many small molecular, anti-
cancer drugs have been encapsulated into PEGylated PLGA nanoparticles and have been 
evaluated in vitro and in vivo to treat various cancers. On the other hand, only few studies are 
aimed at developing antibiotic-loaded PLGA nanoparticles [18,19] to improve the treatment 
of bacterial infections although it offers significant benefit. Since plasma concentrations of 
most antibiotics need to be constant, sustained release of drugs from PLGA-based 
nanoparticles could thus potentially improve the treatment efficacy. Moreover, nanoparticles 
might enhance the intracellular delivery of antibiotics for some intracellular pathogens [20]. 
Such drug carrying nanoparticles have to enter cells to reach the site of action. The membrane 
of the cellular targets of therapeutic agents strongly influences the effectiveness of a drug by 
controlling or modulating such processes as transport, distribution, and accumulation. 
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Investigation of the interaction between an active agent or its carrier and the biomembrane is 
therefore of great interest [2]. The interfacial properties which influence the interactions in 
biological environments might be conveniently investigated using simplified models of 
complex cell membranes [21]. The bilayer [22] or lipid monolayer systems are widely used to 
characterize quantitatively the membrane affinity of bioactive molecules and reveal the 
resulting structural changes [23-27]. Nevertheless, the interaction of drug delivery NPs with 
lipid monolayer is rarely investigated although such studies could be effectively used in 
developing functionalized nanocarrier systems [2,25,28]. 
In the present work we describe the encapsulation of a new antitubercular drug 
candidate (TB515) into PLGA nanoparticles. The cellular uptake and the intracellular efficacy 
against Mycobacterium tuberculosis (Mtb) of the drug and the drug loaded nanoparticulate 
systems were compared. Applying a new surface modification method we tried to enhance the 
membrane affinity and cellular uptake of the drug carrying PLGA nanoparticles. This method 
allows the modification of the charge character of the nanoparticle surface and provides 
surface functional groups for chemical reactions used for targeting. Meanwhile the colloid 
stability of the nanoparticulate system is maintained since the polymer structure around the 
particles is only slightly varied.  
 
 
2 Materials and methods 
2.1 Materials 
Poly(DL-lactic-co-glycolic acid), PLGA with 50% of lactic and 50% of glycolic content (Mw: 
50,000–75,000), obtained from Sigma–Aldrich, Hungary. 
Poly(ethylene oxide)/poly(propylene oxide)/poly(ethylene oxide), PEO–PPO–PEO triblock 
copolymer, Pluronic 127 (Mw: 12600) (provided by BASF HungariaKft.), was applied as 
received. The composition of the Pluronic 127 is characterized by the length of the central 
hydrophobic poly(propylene oxide) (PPO) block (Mw: 3248) and the PEO content (70%) of 
the molecule. Amino terminated Pluronic (Pluronic 127-amine) was prepared from 
Pluronic 127 in two steps. First, terminal hydroxyl groups were modified to aldehyde groups 
by partial oxidation then to primary amine groups by reductive amination using ammonium 
chloride and NaCNBH3 [29]. The appearance of terminal amino groups in Pluronic was 
detected by ninhydrin test. The functionalization yield was above 70% according to 13C NMR 
measurements. 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) was purchased from Sigma–Aldrich 
(purity >99%) and used to form the lipid monolayer in the Langmuir trough. A negatively 
charged lipid, 1,2-dipalmitoyl-sn-glycero-3-phospho-(10-rac-glycerol) (sodium salt) (DPPG), 
mixed with DPPC at 25:75% ratio was applied as the a second model lipid system to mimic a 
negatively charged natural bacterial lipid bilayer. 
TB515 molecule which is a derivative of in silico identified potential antibacterial agent was 
purchased from Ubichem (Budapest, Hungary) (Figure 1)[30]. TB515 is rather hydrophobic 
with poor water solubility and estimated logP of 2.9. Labelling is not needed to detect TB515 
in cellular measurements since it is a strong fluorophore. DMSO (Sigma-Aldrich, A.C.S. 
reagent, ≥99.9%) was the solvent for TB515 in spectrophotometric measurements.  
RPMI-1640 medium, Löwenstein-Jensen medium base and the components of the Sula 
medium was from Sigma-Aldrich (St. Louis, MO, USA). HPMI buffer contains 9 mM 
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glucose, 10 mM NaHCO3, 119 mM NaCl, 9 mM HEPES, 5 mM KCl, 0.85 mM MgCl2, 0.053 
mM CaCl2, 5 mM Na2HPO4×2H2O (pH 7.4). 
Chloroform (p.a., purity 99.4%) from Merck, Hungary, was used for preparing the lipid 
spreading solutions. Dichloromethane (HPLC, purity >99.9%) from Merck, Hungary, and 
methanol (HPLC, purity >99.9%) from LGC Promochem were used for cleaning the 
Langmuir trough and barrier. NaCl (p.a., Riedel de Haën) was cleaned by heat treatment at 
600 °C to avoid possible contamination presenting surface activity. Doubly distilled water 
checked by its conductivity (<5 mS) and surface tension (>72.0 mNm-1 at 23 ± 0.5 °C) was 
the subphase in the Langmuir balance experiments. 
 
2.2 Preparation of nanoparticles and drug encapsulation 
PLGA nanoparticles were prepared by the nanoprecipitation method similar to that employed 
previously [19,28]. Briefly PLGA was dissolved in acetone to a concentration of 10 gL-1. In 
the case of drug encapsulation the TB515 was also dissolved in the PLGA solution. The 
organic solution was added dropwise to an aqueous solution of polymeric stabilizer under 
magnetic stirring (500 rpm). Nanoparticles were formed and stirring was continued overnight 
to achieve the complete evaporation of acetone. After evaporation of the organic solvent the 
particle suspension was centrifuged at 3500 g for 10 min to remove the possible polymer 
aggregates and precipitated drug.The amount of sediment in this step was always less than 5% 
of the whole solid content [19]. The suspension of nanoparticles was further purified by 
centrifugation at 12,000 g for 15 min where the supernatant was removed and the pellet 
containing the particles was redispersed with doubly distilled water. This procedure was 
repeated four times. The preparation conditions of nanoparticles are summarized in Tables 1 
and 2. (The preparation of drug loaded samples without the use of Pluronic stabilizer was not 
possible due to the uncontrolled aggregation of the particles during formulation.) 
For the determination of drug content and encapsulation efficiency the purified nanoparticle 
suspension was lyophilized. A known amount of the solid particles was dissolved in DMSO. 
The drug content of the solution was determined spectrophotometrically measuring the 
absorbance at 357 nm. Relating the measured drug amount to the mass of the solid material 
the drug content (%) and encapsulation efficiency (%) were derived. Each experiment was 
repeated three times. 
 
2.3 Characterization of nanoparticles  
Particle size, zeta potential and colloid stability were measured to characterize the 
nanoparticle systems. Pluronic content of the stabilized PLGA nanoparticles was also 
determined spectrophotometrically. 
Average hydrodynamic size and polydispersity of the particles were determined using a 
dynamic light scattering (DLS) system (Brookhaven Instruments, USA).The suspensions of 
nanoparticles were measured at 0.1 gL-1 concentration. The recorded autocorrelation functions 
were analysed by the second order cumulant expansion method. The data were obtained with 
the average of three measurements. 
The Pluronic content of the nanoparticles was determined using the purified suspensions. A 
colorimetric method based on the complex formation between the ethylene oxide segments of 
the surfactant and cobalt thiocyanate was adapted [31] and applied in the following way. 3 g 
of cobalt nitrate and 20 g of ammonium thiocyanate was dissolved in and diluted to 100 mL 
with doubly distilled water. Volumes of 500 μL of a series of standard Pluronic 127 solutions 
in the concentration range of 0.05-2 g L-1 were introduced into 2 mL centrifuge tubes. 200 μL 
of the cobalt thiocyanate was added to the tubes and the solutions were mixed well. 500 μL 
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ethyl acetate was then added to the tubes and the solutions were mixed thoroughly. The 
mixtures were centrifuged at 12000 g for 1 minute. Three phases separated, an upper ethyl 
acetate layer containing the bulk of the surplus reagent, an aqueous layer and the deep blue 
sediment containing the water and ethyl acetate insoluble Pluronic complex. The upper ethyl 
acetate and aqueous layers were aspirated and discarded. The precipitate was washed with 30 
μL of water followed by the aspiration of water. The precipitate was dissolved in 1 mL of 
acetone and the absorbance was measured in a spectrophotometer at 624 nm. The resulting 
calibration curve was used to calculate the Pluronic content of the PLGA nanoparticles. 
The PLGA samples were assayed similar to that of the Pluronic standards. Spontaneous 
aggregation of the particles occurred during the addition of the cobalt thiocyanate reagent. 
With the addition of the ethyl acetate the PLGA dissolved, so the Pluronic amount determined 
using the assay represents the total Pluronic content of the nanoparticles. Tests were carried 
out to check if the presence of PLGA influences the Pluronic concentration determination. 
The results indicated no interference. 
The measurement of electrophoretic mobility of nanoparticles was carried out by means of 
Malvern Zetasizer 4 apparatus. Smoluchowski approximation was used to calculate zeta 
potential from mobility values. Nanosuspensions were surveyed in aqueous salt solution 
(2 mM NaCl). 
The effect of ionic strength on the colloidal stability of PLGA nanoparticles was investigated 
by adding NaCl solution to the suspension with increasing concentration. After incubation 
time of 15 min absorbance was measured with a spectrophotometer at 400 nm. The 
concentration of NaCl where three times higher absorbance was measured comparing to that 
of the original suspension was used to estimate the critical aggregation concentrations (CAC). 
 
2.4 Interaction with lipid monolayers 
2.4.1 Langmuir monolayer studies 
The preparation of the lipid layers and the penetration experiments were carried out using a 
Langmuir trough, KSV MiniMicro, (5x20x0.6 cm3) with two barriers to provide symmetric 
film compression. All measurements were performed at 23 ± 0.5 °C.  
For the preparation of the Langmuir layers 50 μL of lipid solution (0.2 gL-1) was spread onto 
the aqueous subphase and the solvent was allowed to evaporate for 15 min before 
compression. The lipid monolayer was compressed to a given surface pressure (15 or 
25 mNm-1) and at a fixed barrier position aqueous suspension of the polymer nanoparticles 
was injected below the lipid layer to reach a final concentration of 0.025 gL-1 in the subphase. 
The change in surface pressure as the indicator of interaction of nanoparticles with the lipid 
layer was recorded as a function of time for 1 or 2 hrs. The result of penetration into the 
monolayer was given as the average of two independent measurements with a deviation 
<0.5 mNm-1. 
 
2.4.2 AFM of lipid layers 
Langmuir films were transferred onto a hydrophobized glass plates by the Langmuir-Schaefer 
technique. The morphology of the lipid monolayer without and with the penetrated 
nanoparticles was studied with an atomic force microscope (Park Syst. XE-100, South Korea). 
The AFM scans were conducted at 0.3–0.5 Hz scanning rate taken typically at scan window 
of 2.5x2.5 μm2using a cantilever NSC15 (Park Syst.) made of Si3N4with a tip curvature radius 
less than 10 nm. Observations were carried out using noncontact mode in air. 
 
2.5 Antimicrobial effect and cellular uptake 
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2.5.1 Evaluation of antimycobacterial activity 
In vitro antimycobacterial activity of the TB515 compound was determined on M. 
tuberculosis H37Rv (ATCC 27294) by serial dilution in Sula semi-synthetic medium, which 
was prepared in-house (pH 6.5) [30, 32,33]. Compound was added to medium as DMSO 
solutions at ten various doses (range of final concentration was between 0.5 and 100 μg mL-1). 
MIC was determined after incubation at 37 °C for 28 days. MIC was the lowest concentration 
of a compound at which the visible inhibition of the growth of M. tuberculosis H37Rv 
occurred. In order to confirm the growth inhibition colony forming unit (CFU) was 
determined by subculturing from the Sula medium onto drug-free Löwensten-Jensen solid 
medium. Samples were incubated for 28 days.  
 
2.5.2 Cell culturing 
MonoMac6 human monocytic cell line [34] (DSMZ no.: ACC 124, Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) was maintained in 
RPMI-1640 medium containing 10% FCS, 2 mM L-glutamine and 160 µg mL-1 gentamycin 
at 37 °C in 5% CO2 atmosphere.  
 
2.5.3 Cellular uptake studies by flow cytometry and fluorescent microscopy 
The measurement of cellular uptake of the PLGA-D1 and PLGA-D2 (Table 2) was evaluated 
by flow cytometry (BD LSR II, BD Biosciences, San Jose, CA, USA) and fluorescent 
microscopy (Olympus CKX41, Hamburg, Germany) on MonoMac6 human monocytic cell 
line. Cells were harvested in the logarithmic phase of growth and plated on a 24-well tissue 
culture plate (105 cells/1 mL medium/well) 24 hours prior to the experiment. PLGA-D1 and 
PLGA-D2 were dispersed in serum free RPMI medium and running dilutions were prepared. 
The highest concentration of the compounds on the cells was 20 µg ml-1. Cells were incubated 
with compounds for 3hrs (37 °C, 5% CO2 atmosphere). After centrifugation (1000 rpm, 
5 min) supernatant was removed and 100 L 1 mM trypsin was added to the cells. After 
5 min incubation at 37 °C 1 mL 10% FCS/RPMI medium was added then cells were washed 
two times with medium and resuspended in 0.5 mL HPMI. The cellular uptake was 
determined by BD LSR II using 488 nm (Coherent Sapphire, 22 mW) laser. The intracellular 
fluorescence intensity of the cells was measured on channel PE LP550 (emission at λ = 
550 nm). Data were analyzed with FACSDiva 5.0 software (BD Biosciences, San Jose, CA, 
USA). All measurements were performed in duplicates. Parallel with flow cytometry 
measurements microscopic image of the cells were captured with an Olympus CKX41 
microscope. 
 
2.5.4 Infection of MonoMac6 monolayers with M. tuberculosis H37Rv and determination of 
efficacy against intracellular bacteria  
A modified method based on previous works [35,36] was applied [30]. Briefly, MonoMac6 
monocytes (2×105 cells/1 mL medium/well) were cultured with RPMI-1640 medium 
containing 10% FCS in a 24-well plate 24 hours prior to the experiment. Adherent cells were 
infected with M. tuberculosis H37Rv at a multiplicity of infection (MOI) of 10 for 4 hours. 
Nonphagocytosed extracellular bacteria were removed and the culture was washed three times 
with serum free RPMI. The infected monolayer was incubated for 1 day before antitubercular 
treatment. Infected cells were than treated with TB515, PLGA-D1 and PLGA-D2 at 250 M 
and 125 M final concentration, respectively. After 3 days the treatment was repeated with 
fresh solution of the compounds for an additional 3 days. Untreated cells were considered as 
negative control. After washing steps - in order to remove the antituberculars - infected cells 
were lysed with 2.5% sodium dodecyl sulfate solution. The CFU of M. tuberculosis was 
enumerated on Löwenstein-Jensen solid media after 6 weeks of incubation. 
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3 Results and discussion 
3.1 PLGA nanoparticles 
 
Drug loaded or empty polymeric NPs were formed from PLGA by the nanoprecipitation 
method when a water miscible solvent, acetone was used to dissolve both PLGA and the 
hydrophobic drug molecule TB515 (logP = 2.9). The details of recepies are summarized in 
Table 1 and Table 2 for drug loaded samples. Pluronic 127 and its amine derivative 
Pluronic 127-amine were applied in the aqueous phase as stabilizer in various amounts. 
Sample 0 was also prepared without stabilizer for comparison.  
The NPs obtained were characterized by dynamic light scattering and zeta-potential 
measurements (Tables 1 and 2). The mean diameter of the Pluronic stabilized NPs was around 
150 nm, while without stabilizer somewhat smaller particles were formed with a mean 
diameter of 139 nm. The particle size was in the same range for drug loaded NPs. All of the 
samples showed a narrow size distribution with a polydispersity about 0.05. The PI was below 
0.1 even for the bare NPs.  
The Pluronic content of the NPs was obtained as 1.0 ± 0.1% (w/w) applying the stabilizer at 
concentration of 0.1 gL-1 (samples 1-3) while 2.2 ± 0.3% (w/w) at 1.0 gL-1 Pluronic 
concentration (samples4-6). Previous analysis performed by XPS technique showed that the 
surface layer of PLGA particles is rich in Pluronic component [28]. Supposing that the 
Pluronic is localized on the surface of the NPs the calculated surface concentration of 
Pluronic is found to be in the range of 0.6-1.3 mg/m2 for the stabilized PLGA NPs. These 
values are in good agreement with adsorbed amount of Pluronics 0.5 and 1.7mg/m2 reported 
on moderately hydrophobic surfaces such as carbon black [37] and hydrophobized silica [38], 
respectively. 
Considering the charge character, the bare NPs presented the highest zeta-potential due to the 
surface carboxylic groups of PLGA. The absolute value decreased as expected [4,5,15] when 
the particle surface was covered with Pluronic layer. It is notable, that for samples (no. 4, 5 
and 6) when the higher amount of Pluronic was applied the surface charges were more 
effectively shielded by the polymer chains. The other effect which can also be observed in 
zeta-potential values is the presence of Pluronic 127-amine in the surface layer (samples no. 
2,3,5,6) which resulted in further decrease of zeta-potential comparing to the cases when the 
same amount but unmodified Pluronic 127 was used (samples no. 1 and 4). For the drug 
loaded NPs the zeta-potential values show the similar influence of the application of 
Pluronic 127-amine. 
The above data suggest that the composition of surface layer formed on the PLGA NPs is in 
correlation with the type and amount of stabilizer applied in the course of nanoprecipitation 
process. That allows the design of surface charge character within a given range by varying 
the ratio of the two Pluronic compounds. 
The adsorbed layer of Pluronic on PLGA rendering the surface hydrophilic is responsible for 
the advantageous protein repellent property and the ability of avoiding RES as it was 
demonstrated in several works [5,6,38]. At the same time it contributes to the excellent steric 
stabilization of the NP system. Colloidal stability is generally characterized by the 
determination of critical aggregation concentration (CAC) [15,39]. The stability of the PLGA 
NP systems presented in Table 1 was checked by the turbidity measurements. When adding 
NaCl electrolyte with increasing concentration to the nanosuspension no detectable 
aggregation was found up to 1.5 M NaCl for systems no. 1 to 6.  
The presence of Pluronic provides steric stability to the particles by forming a hydrated layer 
on the surface. The PLGA NPs without stabilizer (sample 0) however, showed aggregation at 
0.03 M NaCl. 
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Nanosuspension prepared with Pluronic or Pluronic-amine proved to be similarly stabilized. 
Consequently, surface modification with Pluronic 127 and Pluronic 127-amine allows 
controlling the charge character of the surface in a certain range and offering functional 
groups for chemical coupling reactions preserving meanwhile the colloid stability of the 
system.  
 
3.2 Drug encapsulation 
 
TB515 drug candidate was encapsulated into the PLGA NPs according to the conditions 
presented in Table 2. About 1.5% drug content was achieved with encapsulation efficiency 
above 30%. The expected maximum drug content calculated from the initial PLGA/drug ratio 
was 2.5% for these cases. Increasing the drug loading significantly the drug content could be 
enhanced close to double but with drastically reduced encapsulation efficiency. Therefore the 
PLGA-D1 and PLGA-D2 systems were selected for further in vitro studies. 
 
3.3 Membrane affinity 
 
DPPC which is the primary phospholipid in the mammalian cell membrane and a significant 
component of alveolar fluid was chosen to form the lipid monolayer as membrane model. 
Since the charge is described as important parameter to influence the interaction with cell 
membrane and govern the cellular uptake [3,40,41] DPPC mixed with DPPG was also used to 
represent the charged membrane model in the penetration experiments. 
The interaction of NPs with lipid layers was studied in Langmuir-balance experiments, where 
the adsorption and/or penetration of the particles into the lipid layer is the indication of their 
membrane affinity. The incorporation of NPs into the lipid layer was visualized by AFM after 
the penetrated layer was transferred to a solid support (Figure 2). The image of corresponding 
lipid layer without nanoparticle penetration is also shown for comparison. The appearance of 
particles in the lipid layer is a direct evidence of the interaction since the NPs were introduced 
into the subphase, and the transfer was performed using the Langmuir-Schaefer (horizontal) 
technique where the solid support does not come into contact with the subphase.  
In order to characterize the degree of interaction, the change in surface pressure was detected 
following the NP injection below the compressed lipid layer. Penetration curves are plotted 
and compared for differently stabilized NP systems in Figures 3-5. The concentration of the 
NPs was the same in all penetration experiments.  
Penetration of three types of NPs are displayed in Figure 3. DPPC layer was compressed to 
25 mNm-1 which is close to the value considered as monolayer-bilayer equivalence pressure. 
There is practically no interaction between the bare PLGA particles and DPPC layer, while 
the Pluronic 127-amine modified PLGA particles resulted in significant and steady surface 
pressure increase (sample no. 3). The adsorption/penetration of the NPs was greatly increased 
when the higher amount of stabilizer was applied for surface coating (sample no. 6).  
The influence of stabilizer type on the membrane affinity is shown in Figure 4. The initial 
surface pressure of DPPC film (15 mNm-1 in this case) increased due to interaction with 
Pluronic 127 stabilized NPs (sample no. 4) but the penetration is further improved when the 
coating was formed from Pluronic 127-amine (sample no. 6). The role of electrostatic 
interaction in membrane affinity was revealed when penetration of Pluronic 127-amine 
stabilized NPs (sample no. 3) was compared for DPPC and DPPC+DPPG lipid layers (Figure 
5). The above penetration experiments show that Pluronic and Pluronic-amine surface 
coatings are suitable for substantial enhancement of the interaction with model lipid 
membrane. 
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Since the PLGA NPs are coated with Pluronic block copolymers it is worth to discuss 
their behaviour taking into consideration the results on corresponding molecular interactions 
obtained earlier [23]. The adsorption of dissolved Pluronics with various block ratios onto 
lipid membrane was investigated and Pluronic 127 proved to be the most effective in 
penetration experiments. The high affinity was explained by the presence of long PPO and 
PEO chains. It was concluded that the length of PPO block is crucial for the ability to 
penetrate the lipid monolayer even at high surface pressure. On the other hand, interaction 
with the lipid molecules can occur in the lipid headgroup region and also some 
interpenetration of the PEO blocks into the lipid monolayers can contribute to the 
incorporation. 
Improved cellular uptake by application of Pluronics has already been reported for 
various drug delivery systems. Those include protein modification by Pluronic block 
copolymers which enhanced intracellular delivery of proteins and brain delivery in vivo [42]. 
Pluronic also enhanced cellular uptake and nuclear entry of polyplex-delivered DNA [43]. It 
was a question however,whether Pluronic 127 might help to transfer PLGA NPs into cells and 
reach the M. tuberculosis within the cell. In these in vitro experiments the drug loaded 
Pluronic and Pluronic-amine coated NPs (PLGA-D1 and PLGA-D2, respectively) were 
investigated and compared to the effect of pure drug. 
 
3.4 In vitro experiments 
 
Antitubercular effect of TB515 
The in vitro antimycobacterial activity of the compound was characterized by the 
determination of the minimal inhibitory concentration (MIC) using M. tuberculosis H37Rv 
culture with 4-week exposure period. TB515 was effective against the bacteria and exhibited 
the MIC value as 5 µg/mL; 19 μM. The minimum inhibitory concentration of compound 
TB515 was determined as the lowest concentration that could inhibit visible bacterial growth. 
Considering that M. tuberculosis is an intracellular pathogen as a host cell (macrophage) 
model we used human monocytic MonoMac6 cells. MonoMac6 was established as a cell line 
which appears to have phenotypic and functional characteristic of mature blood monocytes. 
MonoMac6 cells are attached to the tissue culture plate’s well surface without any treatment 
after hours as a homogeneous cell population. Therefore infected MonoMac6 cell line is an 
accepted model to determine intracellular activity of antituberculars. Cellular uptake tests 
were evaluated using the same cell line [30, 35, 36]. 
 
Cellular uptake of TB515 and encapsulated TB515 into PLGA nanoparticles 
Cellular uptake was evaluated on MonoMac6 human monocytic cell culture using flow 
cytometry (BD LSRII, Figure 6) and fluorescent microscopy (Olympus CKX41). In order to 
rule out the possible contribution of adhesion of the nanoparticles to the MonoMac-6 cellular 
surface, the uptake rate was evaluated following treatment with trypsin and extensive 
washing, to remove plasma membrane-bound nanoparticles. The treatment of MonoMac6 
monocytic cells with PLGA-D1 and PLGA-D2 has resulted in intense intracellular 
fluorescence, suggesting that both PLGA-D1 and PLGA-D2 nanoparticles were internalized 
by the MonoMac-6 cells, Figure 7. The internalization rates of PLGA-D2 was somewhat 
higher than the rates of PLGA-D1 formulation, indicating the higher cellular transport 
potential of PLGA-D2 nanoparticles. 
 
Intracellular killing of M. tuberculosis 
In vitro activity of new TB515 antitubercular compound on M. tuberculosis H37Rv culture is 
valuable (5 g/mL; 19 µM), but it is crucial that the compound is efficient against 
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intracellularly replicating bacteria, too. Intracellular efficacy of TB515, PLGA-D1 and 
PLGA-D2 was evaluated on infected MonoMac6 human monocytes. The infected cells were 
than treated with TB515, PLGA-D1 and PLGA-D2. After 3 days the treatment was repeated 
with fresh solution of the compounds for an additional 3 days. Untreated infected cells were 
considered as negative control.  
Compound TB515 was tested on infected MonoMac-6 cells using a concentration of 125 
g/mL (25 x MIC), and 250 g/mL (50 x MIC). At these concentrations compound TB515 
was able to reduce the number of CFU compared to untreated control in a concentration 
dependent manner. 
Taking into consideration the drug content of PLGA NPs the final concentration of drug was 
adjusted to 125 g/mL in the case of PLGA-D1 and PLGA-D2. Using the PLGA-D1 and 
PLGA-D2 at 125 µM concentration gratifying intracellular inhibition was detected. 
Significantly reduced CFU was enumerated compared to CFU of the untreated control cells. 
The TB515 loaded nanoparticles were proved to be more effective than the free compound 
TB515 since the reduction of the intracellular growth of M. tuberculosis achieved by PLGA-
D1 and PLGA-D2 at 125 μM concentration is comparable to reduction obtained by treatment 
with TB515 at 250 μM concentration. 
No significant difference was observed between the activity of PLGA-D1 and PLGA-D2. 
 
According to the results, preparation of polymeric nanoparticles has improved the 
intracellular efficacy of compound TB515 on M. tuberculosis H37Rv infected MonoMac-6 
cells probably because of the better intracellular availability of the antitubercular. This may be 
due to the better penetration and cellular uptake rate of nanoparticles into the host cells and 
better delivery of TB515 to its site of action. 
 
4 Conclusions 
Surface modification of PLGA nanoparticles where primary amino groups were 
introduced to the Pluronic surface layer was presented in this work. The nanoparticles showed 
significant interaction with model membrane system depending on the amount of amphiphilic 
polymer applied. 
An antitubercular drug candidate was encapsulated into the PLGA NPs. This 
formulation was successfully taken up by cells and enhanced the availability and efficacy of 
drug which was demonstrated in comparative in vitro experiments.  
The PLGA NPs with functionalized surface layer have a great potential as sustained and 
targeted drug delivery system even at oral or site specific administration like inhalation.This 
surface modification method provides a platform to achieve the active targeting of such NPs 
which are sterically stabilized by their surface layer. This seems to be a promising approach 
since the aggregation stability, the stealth character, and the ability of drug targeting are 
simultaneously present. 
Tuberculosis is still is one of the leading causes of death in the world leading to 8 
million infections every year. The antibiotic-loaded nanoparticles could be an effective 
delivery system to target intracellular infections and to treat or prevent local infections. 
It might be another relevant aspect that both PLGA and Pluronic block copolymers are 
approved by the FDA (Food and Drug Administration) and EMA (European Medicine 
Agency) in various drug delivery systems [20]. Based on these main components PLGA drug 
delivery nanoparticles presented here can be in a good position for further development.  
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Legend to Figures 
 
Figure 1 
Chemical structure of TB515 molecule 
 
Figure 2 
AFM images of DPPC+DPPG lipid monolayer before and after penetration of PLGA 
nanoparticles 
 
Figure 3 
Surface pressure of DPPC layer following introduction of bare PLGA (□)and Pluronic127-
amine stabilized PLGA sample3 (○) and 6 (▽) NPs into the subphase. Initial surface pressure 
is 25 mNm-1. 
 
Figure 4 
Surface pressure of DPPC layer compressed to 15 mNm-1 following introduction PLGA NP 
samples 4(◇) and 6 (▽) into the subphase. 
 
Figure 5 
Surfacepressure of DPPC (□) and DPPC+DPPG layer (○)following introduction of 
Pluronic127-amine stabilized PLGA NPs (sample 3) into the subphase. Initial surface 
pressure is 25 mNm-1. 
 
Figure 6 
Cellular uptake of PLGA-D1 (gray) and PLGA-D2 (black) nanoparticleson MonoMac6 
human monocytic cell line using flow cytometry at various drug concentrations. The SD of 
the data is ±5%. 
 
Figure 7 
Fluorescent microscopy images of MonoMac6 human monocytic cells following treatment 
with PLGA-D1 and PLGA-D2 nanoparticles at two concentrations. 
 
Figure 8 
Colony forming unit (CFU) values determined for Mtb infected MonoMac6 human monocytic 
cells following treatment with pure drug (TB515) and various encapsulated drug formulations 
(PLGA-D1 and PLGA-D2). The intracellular efficacy was compared to lysed untreated 
control cells.  
 
